发明公开
- 专利标题： FUSED PYRIMIDINES AS AKT INHIBITORS
- 专利标题（中）： 简明嘧啶，其的Akt抑制剂
-
申请号： EP10703022.3申请日： 2010-02-05
-
公开(公告)号： EP2396331A1公开(公告)日： 2011-12-21
- 发明人: VENNEMANN, Matthias , BÄR, Thomas , MAIER, Thomas , HÖLDER, Swen , BENEKE, Gerrit , DEHMEL, Florian , ZÜLCH, Armin , STRUB, Andreas , BECKERS, Thomas , INCE, Stuart , REHWINKEL, Hartmut , LIU, Ningshu , BÖMER, Ulf
- 申请人： Bayer Pharma Aktiengesellschaft
- 申请人地址： Müllerstrasse 178 13353 Berlin DE
- 专利权人： Bayer Pharma Aktiengesellschaft
- 当前专利权人： Bayer Pharma Aktiengesellschaft
- 当前专利权人地址： Müllerstrasse 178 13353 Berlin DE
- 优先权： EP09152805 20090213
- 国际公布： WO2010091824 20100819
- 主分类号： C07D487/04
- IPC分类号： C07D487/04 ; A61P35/00 ; A61K31/517
摘要：
The present invention relates to compounds of formula (I), a N-oxide or tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6, R7, R10, m and n have the meanings as given in the description and the claims, which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.
公开/授权文献
- EP2396331B1 FUSED PYRIMIDINES AS AKT INHIBITORS 公开/授权日：2013-10-16
信息查询
